Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation

Leukemia. 2012 Jan;26(1):162-4. doi: 10.1038/leu.2011.181. Epub 2011 Aug 5.

Authors

G Metzgeroth, P Erben, H Martin, S Mousset, M Teichmann, C Walz, T Klippstein, A Hochhaus, N C P Cross, W-K Hofmann, A Reiter

PMID: 21818111
DOI: 10.1038/leu.2011.181

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Antineoplastic Agents / therapeutic use*
Benzamides
Benzenesulfonates / therapeutic use*
Chronic Disease
Drug Resistance, Neoplasm / genetics
Humans
Hypereosinophilic Syndrome / drug therapy*
Hypereosinophilic Syndrome / genetics
Imatinib Mesylate
Male
Middle Aged
Mutation*
Niacinamide / analogs & derivatives
Phenylurea Compounds
Piperazines / therapeutic use*
Pyridines / therapeutic use*
Pyrimidines / therapeutic use*
Receptor, Platelet-Derived Growth Factor alpha / genetics*
Sorafenib
mRNA Cleavage and Polyadenylation Factors / genetics*

Substances

Antineoplastic Agents
Benzamides
Benzenesulfonates
FIP1L1 protein, human
Phenylurea Compounds
Piperazines
Pyridines
Pyrimidines
mRNA Cleavage and Polyadenylation Factors
Niacinamide
Imatinib Mesylate
Sorafenib
Receptor, Platelet-Derived Growth Factor alpha
nilotinib